PL2363140T3 - Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału - Google Patents

Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału

Info

Publication number: PL2363140T3
Authority: PL; Poland
Prior art keywords: treatment; compartment syndrome; tumour; antisecretory; antisecretory protein
Prior art date: 2006-04-27

Application number

PL10188590T

Other languages

English (en)

Inventor

Hans-Arne Hansson

Stefan Lange

Eva Jennische

Tomas Bergström

Original Assignee

Lantmännen As-Faktor Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-27

Filing date

2007-04-27

Publication date

2017-05-31

2007-04-27 Application filed by Lantmännen As-Faktor Ab filed Critical Lantmännen As-Faktor Ab

2017-05-31 Publication of PL2363140T3 publication Critical patent/PL2363140T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Marine Sciences & Fisheries (AREA)
Obesity (AREA)
Dispersion Chemistry (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)

PL10188590T 2006-04-27 2007-04-27 Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału PL2363140T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0600933		2006-04-27
EP10188590.3A EP2363140B1 (en)	2006-04-27	2007-04-27	Antisecretory protein for use in the treatment of compartment syndrome

Publications (1)

Publication Number	Publication Date
PL2363140T3 true PL2363140T3 (pl)	2017-05-31

Family

ID=38655929

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL07748078T PL2040734T3 (pl)	2006-04-27	2007-04-27	Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
PL10188590T PL2363140T3 (pl)	2006-04-27	2007-04-27	Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL07748078T PL2040734T3 (pl)	2006-04-27	2007-04-27	Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału

Country Status (19)

Country	Link
US (2)	US8309513B2 (pl)
EP (2)	EP2363140B1 (pl)
JP (2)	JP5323682B2 (pl)
KR (3)	KR101805973B1 (pl)
CN (3)	CN104689299B (pl)
AT (1)	ATE526031T1 (pl)
AU (1)	AU2007244003B2 (pl)
BR (2)	BRPI0710794A2 (pl)
CA (1)	CA2650589C (pl)
DK (3)	DK2037950T3 (pl)
ES (3)	ES2615515T3 (pl)
IL (1)	IL194774A (pl)
MX (1)	MX2008013774A (pl)
NZ (2)	NZ572256A (pl)
PL (2)	PL2040734T3 (pl)
RU (2)	RU2457853C2 (pl)
SG (1)	SG171601A1 (pl)
WO (1)	WO2007126363A2 (pl)
ZA (2)	ZA200809116B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2008013777A (es)	2006-04-27	2009-02-03	Lantmaennen As Faktor Ab	Usos medicos adicionales de la proteina antisecretora.
DK2037950T3 (da)	2006-04-27	2014-06-30	Lantmännen As Faktor Ab	Yderligere medicinske anvendelser af antisekretorisk protein
RU2458703C2 (ru)	2006-04-27	2012-08-20	Лантменнен Ас-Фактор	Новый подход к лечению повышенного внутриглазного давления
US9962424B2 (en)	2007-04-27	2018-05-08	Lantmännen As-Faktor Ab	Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010065342A1 (en)	2008-11-25	2010-06-10	Temple University	Angiocidin inhibition of tumor cell growth
EP2396024A4 (en) *	2009-02-11	2013-02-27	Lantmaennen As Faktor Ab	USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
ES2887086T3 (es)	2015-07-10	2021-12-21	Lantmaennen Functional Foods Ab	Procedimiento para producir yema de huevo con alto contenido de af-16
KR102268955B1 (ko) *	2016-07-18	2021-06-25	란트만넨 아스-팍토르 아베	항분비 인자 17
US20250177480A1 (en)	2018-06-28	2025-06-05	Lantmännen Medical Ab	Antisecretory Factor for Use in Treatment and/or Prevention of Acute Respiratory Failure
EP3855935A1 (en)	2018-09-28	2021-08-04	Lantmännen Functional Foods AB	A consumable product comprising malted wheat
CN112770643A (zh)	2018-09-28	2021-05-07	兰特门内保健食品公司	包含麦芽化脱壳燕麦的可消耗产品
AU2021243735A1 (en)	2020-03-26	2022-10-13	Lantmännen Functional Foods Ab	A consumable product comprising malted cereals for promoting recovery at physical activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH682716A5 (de) *	1992-01-13	1993-11-15	Christian Fricker	Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en)	1994-12-09	1996-12-17	The Reents Of The University Of California	Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) *	1995-08-24	1998-10-19	Rural Patent Svenska Ab	Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9604251L (sv) *	1996-11-20	1997-12-22	Svenska Lantmaennen Riksfoerbu	Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) *	1998-12-17	2000-09-18	Rural Patent Svenska Ab	NASP-berikad äggula samt dess användning
US7662169B2 (en) *	2000-09-05	2010-02-16	Wittmann Dietmar H	Prosthesis and method for lowering abdominal pressure
GB0322645D0 (en) *	2003-09-26	2003-10-29	Melacure Therapeutics Ab	Use of antisecretory factor peptides
MX2008013777A (es)	2006-04-27	2009-02-03	Lantmaennen As Faktor Ab	Usos medicos adicionales de la proteina antisecretora.
DK2037950T3 (da)	2006-04-27	2014-06-30	Lantmännen As Faktor Ab	Yderligere medicinske anvendelser af antisekretorisk protein
WO2009052478A1 (en) *	2007-10-19	2009-04-23	Trustees Of Boston University	Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide

2007
- 2007-04-27 DK DK07748080.4T patent/DK2037950T3/da active
- 2007-04-27 EP EP10188590.3A patent/EP2363140B1/en active Active
- 2007-04-27 CN CN201510082714.6A patent/CN104689299B/zh active Active
- 2007-04-27 ES ES10188590.3T patent/ES2615515T3/es active Active
- 2007-04-27 AT AT07748078T patent/ATE526031T1/de not_active IP Right Cessation
- 2007-04-27 PL PL07748078T patent/PL2040734T3/pl unknown
- 2007-04-27 WO PCT/SE2007/000413 patent/WO2007126363A2/en not_active Ceased
- 2007-04-27 CA CA2650589A patent/CA2650589C/en active Active
- 2007-04-27 NZ NZ572256A patent/NZ572256A/en not_active IP Right Cessation
- 2007-04-27 ES ES07748080.4T patent/ES2472737T3/es active Active
- 2007-04-27 AU AU2007244003A patent/AU2007244003B2/en active Active
- 2007-04-27 NZ NZ572257A patent/NZ572257A/en not_active IP Right Cessation
- 2007-04-27 DK DK10188590.3T patent/DK2363140T3/en active
- 2007-04-27 CN CN200780014997.4A patent/CN101460187B/zh not_active Expired - Fee Related
- 2007-04-27 BR BRPI0710794-3A patent/BRPI0710794A2/pt not_active IP Right Cessation
- 2007-04-27 SG SG201102875-0A patent/SG171601A1/en unknown
- 2007-04-27 RU RU2008146731/15A patent/RU2457853C2/ru active
- 2007-04-27 EP EP07748078A patent/EP2040734B1/en active Active
- 2007-04-27 KR KR1020147032781A patent/KR101805973B1/ko not_active Expired - Fee Related
- 2007-04-27 MX MX2008013774A patent/MX2008013774A/es active IP Right Grant
- 2007-04-27 CN CN200780014998.9A patent/CN101437533B/zh active Active
- 2007-04-27 DK DK07748078.8T patent/DK2040734T3/da active
- 2007-04-27 KR KR1020087029120A patent/KR20090045148A/ko not_active Ceased
- 2007-04-27 BR BRPI0710858-3A patent/BRPI0710858A2/pt not_active Application Discontinuation
- 2007-04-27 JP JP2009507631A patent/JP5323682B2/ja active Active
- 2007-04-27 KR KR1020147027241A patent/KR101757523B1/ko active Active
- 2007-04-27 ES ES07748078T patent/ES2374712T3/es active Active
- 2007-04-27 RU RU2008146734/15A patent/RU2465914C2/ru active
- 2007-04-27 PL PL10188590T patent/PL2363140T3/pl unknown
2008
- 2008-10-22 IL IL194774A patent/IL194774A/en active IP Right Grant
- 2008-10-23 ZA ZA200809116A patent/ZA200809116B/xx unknown
- 2008-10-23 ZA ZA200809114A patent/ZA200809114B/xx unknown
- 2008-10-27 US US12/289,389 patent/US8309513B2/en active Active
2010
- 2010-11-02 JP JP2010245989A patent/JP5285043B2/ja active Active
2011
- 2011-02-11 US US13/025,702 patent/US8389468B2/en active Active

Also Published As

Publication number	Publication date
AU2007244003A1 (en)	2007-11-08
HK1131738A1 (en)	2010-02-05
JP2011032284A (ja)	2011-02-17
CA2650589A1 (en)	2007-11-08
SG171601A1 (en)	2011-06-29
CN101437533A (zh)	2009-05-20
KR20140141729A (ko)	2014-12-10
ATE526031T1 (de)	2011-10-15
AU2007244003B2 (en)	2012-08-02
CN101460187B (zh)	2014-11-05
KR101805973B1 (ko)	2017-12-06
BRPI0710794A2 (pt)	2011-06-21
KR20140123601A (ko)	2014-10-22
WO2007126363A2 (en)	2007-11-08
IL194774A (en)	2015-07-30
EP2040734B1 (en)	2011-09-28
DK2037950T3 (da)	2014-06-30
PL2040734T3 (pl)	2012-04-30
EP2363140A1 (en)	2011-09-07
DK2363140T3 (en)	2017-03-06
US20110305773A1 (en)	2011-12-15
NZ572256A (en)	2012-02-24
RU2008146731A (ru)	2010-06-10
ES2615515T3 (es)	2017-06-07
ZA200809114B (en)	2009-06-24
EP2040734A2 (en)	2009-04-01
RU2008146734A (ru)	2010-06-10
CN101460187A (zh)	2009-06-17
US8389468B2 (en)	2013-03-05
RU2465914C2 (ru)	2012-11-10
CN101437533B (zh)	2016-10-12
US20090185982A1 (en)	2009-07-23
EP2363140B1 (en)	2016-12-14
JP5323682B2 (ja)	2013-10-23
BRPI0710858A2 (pt)	2011-05-17
CN104689299A (zh)	2015-06-10
JP5285043B2 (ja)	2013-09-11
US8309513B2 (en)	2012-11-13
ZA200809116B (en)	2009-07-29
CA2650589C (en)	2017-06-13
ES2472737T3 (es)	2014-07-02
KR20090045148A (ko)	2009-05-07
RU2457853C2 (ru)	2012-08-10
IL194774A0 (en)	2011-08-01
CN104689299B (zh)	2020-02-21
MX2008013774A (es)	2009-02-03
JP2009535328A (ja)	2009-10-01
NZ572257A (en)	2011-10-28
DK2040734T3 (da)	2012-01-23
WO2007126363A3 (en)	2008-03-13
ES2374712T3 (es)	2012-02-21
KR101757523B1 (ko)	2017-07-12
WO2007126363A8 (en)	2008-10-30

Publication	Publication Date	Title
ZA200809114B (en)	2009-06-24	Antisecretory protein for use in the treatment of compartment syndrome
CY1124298T1 (el)	2022-07-22	Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
BR112019021822A2 (pt)	2020-05-26	Terapia de combinação
EA201890146A1 (ru)	2018-06-29	СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
CR9312A (es)	2008-07-31	Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
EA201290356A1 (ru)	2012-12-28	Композиции для лечения тошноты и рвоты центрального происхождения
CY1111065T1 (el)	2015-06-11	Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
DK2305255T3 (da)	2012-12-10	Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
NO20053782L (no)	2005-09-27	Behandling av kreft med 2-deoksyglukose
ATE511889T1 (de)	2011-06-15	Partikeltherapieanlage
CL2008001932A1 (es)	2009-09-25	Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
EP2571573A4 (en)	2013-12-04	PHOTOTHERAPY BY CAPSULE
NO20091661L (no)	2009-06-02	Anvendelse av pegylert IL-10 for a behandle kreft
MX390506B (es)	2025-03-20	Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
NZ590550A (en)	2013-05-31	Inhibitors of Apoptosis (IAP) for treating cancer
NO20071426L (no)	2007-06-18	Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
CY1117394T1 (el)	2017-04-26	Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων
NO20075849L (no)	2008-01-14	Fremgangsmater og preparater til behandling eller forebygging av kreft
BR112022012283A2 (pt)	2022-08-30	Combinações
WO2011056566A3 (en)	2011-06-30	Compounds and methods for treatment of cancer
NZ625673A (en)	2015-11-27	Use of a neuregulin to treat peripheral nerve injury
EA200900735A1 (ru)	2010-02-26	Применение слитого антигена mage a3-белок d в имунотерапии в сочетании с хирургическим вмешательством, химиотерапией или радиотерапией для лечения рака
WO2008144659A3 (en)	2009-04-09	Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
BR112022012284A2 (pt)	2022-08-30	Combinações
DK1720540T3 (da)	2008-10-06	Satraplatin til behandling af resistente tumorer eller tumorer, der er vanskelige at behandle